<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="80630">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01928147</url>
  </required_header>
  <id_info>
    <org_study_id>PPI-383-101</org_study_id>
    <nct_id>NCT01928147</nct_id>
  </id_info>
  <brief_title>A Phase 1a/1b Study of PPI-383 in Healthy Adults and Hepatitis C Patients</brief_title>
  <official_title>A Phase Ia and Ib Dose-Ranging Study to Assess the Safety, Pharmacokinetics, and Antiviral Efficacy of PPI-383 in Healthy Adults and Hepatitis C Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Presidio Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Presidio Pharmaceuticals, Inc.</source>
  <oversight_info>
    <authority>United Kingdom: Research Ethics Committee</authority>
    <authority>United Kingdom: Medicines and Healthcare Products Regulatory Agency</authority>
    <authority>France: Agence Nationale de Sécurité du Médicament et des produits de santé</authority>
    <authority>France: Committee for the Protection of Personnes</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      PPI-383 is an antiviral agent (an inhibitor of the hepatitis C virus NS5B polymerase) that
      is being developed as a potential treatment for hepatitis C virus infection. This study is
      being done to assess the dose-related safety and tolerance of PPI-383 when given to healthy
      volunteers for up to 5 days (Part I of the study) and to hepatitis C patients for up to 3
      days (Part II). In addition, the study will assess how much PPI-383 is absorbed into the
      bloodstream. In Part II, the dose-related effect of PPI-383 on the amount of hepatitis C
      virus in patients' bloodstream (serum HCV RNA levels) also will be assessed.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2013</start_date>
  <completion_date type="Anticipated">June 2014</completion_date>
  <primary_completion_date type="Anticipated">April 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Safety and tolerability, as measured by clinical adverse events and laboratory assessments</measure>
    <time_frame>Part I, up to day 12; and Part II, up to day 17</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>PPI-383 plasma levels</measure>
    <time_frame>Part I, up to day 12; and Part II, up to day 17</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>serum HCV RNA levels</measure>
    <time_frame>Part II, up to day 17</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">144</enrollment>
  <condition>Hepatitis C, Chronic</condition>
  <arm_group>
    <arm_group_label>PPI-383 single dose escalation in healthy volunteers</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>There will be up to 10 sequential single dose cohorts to assess the bioavailability of different doses and formulations;  a food effect cohort will be included.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PPI-383 multiple doses in healthy volunteers</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Upon completion of the single dose cohorts, an additional cohort will receive the highest well-tolerated dose from the single dose cohorts or placebo once daily for five days;  up to 2 additional cohorts may receive multiple doses of different formulations or different regimens</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PPI-383 multiple dose escalation in HCV Subjects</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Upon completion of the single and multiple dose healthy volunteer cohorts, there will be 3, and potentially 4, sequential cohorts of HCV patients</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PPI-383</intervention_name>
    <arm_group_label>PPI-383 single dose escalation in healthy volunteers</arm_group_label>
    <arm_group_label>PPI-383 multiple doses in healthy volunteers</arm_group_label>
    <arm_group_label>PPI-383 multiple dose escalation in HCV Subjects</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>PPI-383 single dose escalation in healthy volunteers</arm_group_label>
    <arm_group_label>PPI-383 multiple doses in healthy volunteers</arm_group_label>
    <arm_group_label>PPI-383 multiple dose escalation in HCV Subjects</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Part I volunteers (single and multiple dose) - key inclusion criteria

          -  Healthy males

          -  Age 18 to 55 years

          -  Body mass index (BMI)18 to 32 kg/m2

        Part II patients- key inclusion criteria

          -  Males, or females of non-childbearing potential

          -  Age 18 to 65 years

          -  Chronic hepatitis C, and absence of other known liver disease

          -  Seropositive for HCV antibody (HCV Ab) or HCV RNA at least once previously

          -  Seropositive for HCV Ab at screening

          -  Serum HCV RNA &gt; 5 log10 IU/mL at screening

          -  HCV gt-1

          -  Treatment-naïve for hepatitis C:

          -  BMI 18 to 35 kg/m2

          -  Otherwise in good health, without severe or clinically significant chronic or
             recurrent conditions requiring frequent medical intervention or continual
             pharmacologic management, except for anti-hypertensive use

          -  No medical or psychosocial conditions that would potentially interfere with the
             subject's ability to comply with the study assessments or visit schedule.

        Part II patients - key exclusion criteria

          -  Seropositive for human immunodeficiency virus (HIV) antibody or hepatitis B virus
             (HBV) surface antigen (HBsAg)

          -  Signs or symptoms of decompensated liver disease

          -  Evidence of cirrhosis or hepatocellular carcinoma

          -  Diabetes Mellitus treated with insulin or hypoglycemic agents

          -  Asthma requiring hospital admission within the preceding 12 months

          -  History of alcohol abuse or illicit drug use which could interfere with a patient's
             compliance with the protocol requirements

          -  Any of the following laboratory values at screening

               -  Haemoglobin (Hgb) &lt;11 g/dL in women or 12 g/dL in men

               -  White blood cell count &lt;4,000/mm3

               -  Absolute neutrophil count (ANC) &lt; 1800 per mm3

               -  Platelet count &lt;100,000 per mm3

               -  Serum creatinine &gt; upper limit of normal (ULN) at the central study laboratory

               -  Serum albumin &lt;3.4 g/dL

               -  Total bilirubin &gt;2.0 mg/dL

          -  Clinically significant abnormality in the electrocardiograms (ECGs) at screening
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nathaniel Brown, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Presidio Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Presidio Pharmaceuticals</last_name>
    <phone>415-655-7581</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Investigational site</name>
      <address>
        <city>London</city>
        <zip>NW3 2QG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational site</name>
      <address>
        <city>London</city>
        <zip>W2 1NY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational site</name>
      <address>
        <city>London</city>
        <zip>UE1 2AD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational site</name>
      <address>
        <city>London</city>
        <zip>SE5 9RS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational site</name>
      <address>
        <city>Nottingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lorna Patrick</last_name>
      <phone>44 (0)115 931 5509</phone>
    </contact>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>August 2013</verification_date>
  <lastchanged_date>August 20, 2013</lastchanged_date>
  <firstreceived_date>August 19, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>NS5B polymerase inhibitor</keyword>
  <keyword>Phase 1</keyword>
  <keyword>Genotype 1</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
